Indian Pharmaceutical Alliance (IPA) - the industry body that represents large domestic pharmaceutical companies has sought the government to exclude low-priced scheduled products from price control citing viability issues in the wake of high raw material and logistics costs.
In an interview to ET, Samir Mehta, IPA president and chairman of Torrent Pharma said manufacturers of scheduled medicines are incurring losses because of the rising volatility of raw material prices and lack of flexibility to raise prices, and may have to cut back on supplies or have to exit products altogether.
This article was originally published on The Economic Times